prevention of venous thromboembolism surgical care improvement project dale w. bratzler, do, mph...

41
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President and CEO Oklahoma Foundation for Medical Quality

Upload: bryce-jacobs

Post on 17-Dec-2015

215 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Prevention of Venous Thromboembolism

Surgical Care Improvement Project

Dale W. Bratzler, DO, MPH

QIOSC Medical Director

Dale W. Bratzler, DO, MPH

President and CEO

Oklahoma Foundation for Medical Quality

Page 2: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Why is there a need to measure the quality of hospital care?

• The passive strategy of guideline publication and dissemination does not effectively change clinical practice– The time lag between publication of evidence

and incorporation into care at the bedside is very long

– Variations in care and delivery of care that is not consistent with evidence-based recommendations is well documented

Bratzler DW. Development of national performance measures on the prevention and treatment of venous thromboembolism. J Thromb Thrombolysis. 2009 (in press)

Page 3: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Prevention of Venous Thromboembolism (VTE) – an example

• The American College of Chest Physicians published their first consensus conference on antithrombotic therapy in 1986– In 2008 published their 8th edition of the

evidence-based guideline

– Despite all of these published editions…..

VTE - the most common preventable cause of hospital death- 2/3 of all cases occur in recently hospitalized patients

- up to 3/4 of all cases of PE death are a result of hospitalization

Page 4: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Prevention of Venous Thromboembolism – an example

• Multiple studies that have included hospital medical record audits show consistent underuse of VTE prophylaxis– Up to 2/3 of patients with hospital-acquired

VTE did not receive prophylaxis

• Audits of patients receiving treatment for confirmed VTE show non-compliance with guideline-recommended treatment

Bratzler DW. Development of national performance measures on the prevention and treatment of venous thromboembolism. J Thromb Thrombolysis. 2009 (in press)

Page 5: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

“The best estimates indicate that 350,000 to 600,000 Americans each year suffer from DVT and PE, and that at least 100,000 deaths may be directly or indirectly related to these diseases. This is far too many, since many of these deaths can be avoided. Because the disease disproportionately affects older Americans, we can expect more suffering and more deaths in the future as our population ages–unless we do something about it.”

Page 6: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Risk Factors for DVT or PENested Case-Control Study (n=625 case-control pairs)

Surgery

Trauma

Inpatient

Malignancy with chemotherapy

Malignancy without chemotherapy

Central venous catheter or pacemaker

Neurologic disease

Superficial vein thrombosis

Varicose veins/age 45 yr

Varicose veins/age 60 yr

Varicose veins/age 70 yr

CHF, VTE incidental on autopsy

CHF, antemortem VTE/causal for death

Liver disease

00 55 1010 1515 2020 2525 5050Odds ratioOdds ratio

Page 7: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Most hospitalized patients have at least one additional risk factor for VTE

Risk Factors for VTE

• Surgery

• Trauma

• Immobility, paresis

• Malignancy

• Cancer therapy

– hormonal therapy, chemotherapy or radiotherapy

• Previous VTE

• Increasing age

• Pregnancy and post-partum period

• Estrogen-containing oral contraception or HRT or SERM

• Acute medical illness

• Heart failure

• Respiratory failure

• Inflammatory bowel disease

• Nephrotic syndrome

• Myeloproliferative disorders

• Obesity

• Smoking

• Varicose veins

• Central venous catheterization

• Inherited or acquired thrombophilia

• Travel

Geerts W et al. Chest. 2004;126:338S-400S.

Page 8: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

VTE Facts

• Almost half of the outpatients with VTE had been recently hospitalized

• Less than half of the recently hospitalized patients had received VTE prophylaxis during their hospitalizations

• About half had a length of stay (LOS) of < 4 days

Medical Hospitalization

Only

Hospitalization with Surgery

Ou

tpat

ien

ts W

ith

VT

E,

% 70

60

50

40

30

20

10

0

Days After Discharge

0-29 30-59 60-90

Goldhaber S. Arch Intern Med. 2007;167:1451-2.Spencer FA et al. Arch Intern Med. 2007;167(14):1471-5.

Page 9: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Categories of Risk for Venous Thromboembolism in Patients

Low risk:• Minor surgery in mobile patients

Moderate risk:• Most medically ill, general, open gyn

or urologic surgery patients

High risk:• Cancer surgery, hip or knee arthroplasty,

hip fracture surgery, major trauma or spinal cord injury

Geerts W et al. Chest. 2008;133:381S-453S.

Page 10: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Mechanical Methods of VTE Prevention

• Graduated Compression Stockings (GCS)

• Intermittent Pneumatic Compression Devices (IPCs)

• Venous Foot Pump (VFP)

Page 11: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Pharmacologic Options for VTE Prevention

• Unfractionated Heparin (UFH)

• Low-Molecular Weight Heparins (LMWHs)

• Pentasaccharide (Fondaparinux)

• Warfarin

Page 12: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Prophylaxis Against Fatal Post-Operative PE With LDUH: A Multicenter, Prospective, Randomized Trial

Study population: 4,121 patients age > 40 y undergoing a variety of elective major surgical procedures

P < 0.005

• 5,000 IU SC 2 hours preoperatively and 8 hours thereafter for 7 days.

Pat

ien

ts w

ith

PE

(%

)

Kakkar VV et al. Lancet. 1975;2:45-51.

0.77

0.097

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

Control (N = 2,076) UFH* (N = 2,045)

Page 13: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Mechanical Thromboprophylaxis

Geerts WH et al. Chest. 2008;133(6 Suppl):381S-453S.

• For particularly high-risk surgery patients with multiple risk factors, pharmacologic method should be combined with mechanical method (GCS, IPC) (1C)

• Use mechanical methods for patients with high bleeding risk (1A), when bleeding risk decreases substitute or add pharmacological thromboprophylaxis (1C)

Page 14: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Problems with Mechanical Prophylaxis

• Non-compliance– ~ 50% of med-surg floors– ~80% in intensive care units

• Most common reasons for non-compliance– ~80% of the time, not on the patient– ~20% of the time, on the patient but not turned on

Page 15: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

VTE ProphylaxisGrade 1 Recommendations

Surgery* Recommended Prophylaxis

General surgery Low-dose unfractionated heparin (LDUH)

Low molecular weight heparin (LMWH)

Fondaparinux (effective 10/01/07)

LDUH or LMWH combined with IPC or GCS

General surgery with a reason for not administering pharmacologic prophylaxis documented

Graduated Compression stockings (GCS)

Intermittent pneumatic compression (IPC)

Gynecologic surgery Low-dose unfractionated heparin (LDUH)

Low molecular weight heparin (LMWH)

Factor Xa inhibitor

Intermittent pneumatic compression devices (IPC)

LDUH, LMWH, or factor Xa inhibitor combined with IPC or GCS

*Open surgical procedure > 30 minutes requiring in-hospital stay > 24 hours postoperative.

*Limited to those patients who have an anesthesia duration of at least 60 minutes, and a hospital stay of at least three calendar days (two nights in the hospital).

Page 16: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

VTE ProphylaxisGrade 1 Recommendations

Surgery Recommended Prophylaxis

Urologic surgery Low-dose unfractionated heparin (LDUH) 5000 units bid or tid

Low molecular weight heparin (LMWH)

Factor Xa inhibitor (fondaparinux)

Intermittent pneumatic compression devices (IPC)

Graduated compression stockings (GCS)

LDUH, LMWH, or factor Xa inhibitor combined with IPC or GCS

Elective total hip replacement

Low molecular weight heparin (LMWH)

Factor Xa inhibitor (fondaparinux)

Adjusted-dose warfarin (INR target 2.5, range 2.0-3.0)

Elective total knee replacement

Low molecular weight heparin (LMWH)

Factor Xa inhibitor (fondaparinux)

Adjusted-dose warfarin (INR target 2.5, range 2.0-3.0)

Intermittent pneumatic compression devices (IPC)

Venous foot pumps (VFP)

Page 17: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

VTE ProphylaxisGrade 1 Recommendations

Surgery Recommended Prophylaxis

Hip fracture surgery Low molecular weight heparin (LMWH)

Factor Xa inhibitor

Adjusted-dose warfarin (INR target 2.5, range 2.0-3.0)

Low-dose unfractionated heparin (LDUH)

Hip fracture surgery (HFS) or elective total hip replacement with a reason for not administering pharmacologic prophylaxis documented

Graduated Compression stockings (GCS) (HFS only)

Intermittent pneumatic compression (IPC)

Venous foot pumps (VFP)

Intracranial neurosurgery IPC with or without GCS

Low-dose unfractionated heparin (LDUH)

Postoperative Low molecular weight heparin (LMWH)

LDUH or LMWH combined with IPC or GCS

*Open surgical procedure > 30 minutes requiring in-hospital stay > 24 hours postoperative.

Page 18: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Performance Measurement Does Not Happen without Controversy

Page 19: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Summary American Academy of Orthopedic Surgeons (AAOS) Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism in Patients Undergoing Total Hip or Knee Arthroplasty

Standard risk PE, Standard risk Bleeding* aspirin LMWH synthetic pentasaccharides warfarinLevel III, Grade B recommendation

Standard risk PE, Elevated risk Bleeding aspirin warfarin noneLevel III, Grade C recommendation

Elevated risk PE, Standard risk Bleeding LMWH synthetic pentasaccharides warfarinLevel III, Grade B recommendation

Elevated risk PE, Elevated risk Bleeding aspirin warfarin noneLevel III, Grade C recommendation

SCIP VTE 1 Performance MeasureHip or Knee Arthroplasty

No Bleeding Risk Documented Documented Bleeding Risk

Hip or knee arthroplasty: LMWH synthetic pentasaccharides warfarin

Knee arthroplasty only: intermittent pneumatic compression devices venous foot pump

Mechanical Prophylaxis[any other modality (including aspirin or warfarin) can be added]

Page 20: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

What else does the AAOS guideline say?

• They do NOT recommend the use of aspirin alone– They recommend the use of mechanical prophylaxis

started in the operating room or immediately postoperatively in all patients – continued to discharge

– They recommend pharmacologic prophylaxis with LMWH, factor Xa inhibitor, or warfarin in high risk patients

• previous history of cancer, thromboembolism, hypercoagulable states such as polycythemia, spinal cord injury patients, multi-trauma patients, and genetic predisposition

Page 21: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

VTE Prophylaxis

• Other issues– Timing of prophylaxis– Neuraxial anesthesia– Renal insufficiency– Duration of prophylaxis

Page 22: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President
Page 23: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Venous ThromboembolismStatement of Organization Policy

“Every healthcare facility shall have a written policy appropriate for its scope, that is evidence-based and that drives continuous quality improvement related to VTE risk assessment, prophylaxis, diagnosis, and treatment.”

Page 24: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Measure specifications available at: www.qualitynet.org

Page 25: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Electronic Submission of Performance Measures

In the recently published final IPPS rule for fiscal year 2010, CMS has announced that through an interagency agreement with the Office of the National Coordinator for Healthcare Information Technology, they are developing interoperable standards for electronic medical record submission of the newly-endorsed VTE measures. Vendors of electronic medical record systems would be able to code their systems with the new specifications by the end of 2009.

Centers for Medicare & Medicaid Services. Medicare Program; Changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year 2010 Rates; and Changes to the Long-Term Care Hospital

Prospective Payment System and Rate Years 2010 and 2009 Rates. Available at: http://www.federalregister.gov/OFRUpload/OFRData/2009-18663_PI.pdf. Accessed 10 August 2009.

Page 26: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Improving Use of VTE Prophylaxis

Page 27: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Strategies to Improve VTE Prophylaxis

• Hospital policy of risk assessment or routine prophylaxis for all admitted patients– Most will have risk factors for VTE and should

receive prophylaxis– Preprinted protocols for surgical patients

Page 28: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Electronic Alerts to Prevent VTE among Hospitalized Patients

Control Alert group group P

No. 1,251 1,255

Any prophylaxis 15 % 34 % <0.001

VTE at 90 days 8.2 % * 4.9 % 0.001

Major bleeding 1.5 % 1.5 % NS

Kucher – NEJM 2005;352:969

• Hospital computer system identified patient VTE risk factors

• RCT: no physician alert vs physician alert

* NNT = 30

Page 29: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Improving Compliance with Treatment Protocols

• Use of standardized protocols, nomograms, algorithms, or preprinted orders– Address overlap (either 5 days in hospital or

discharge on overlap)– When used, UFH should be managed by

nomogram/protocol, and the protocol should ensure routine platelet count monitoring

Page 30: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Essential Elements for Improvement

• Institutional support

• A multidisciplinary team or steering committee

• Reliable data collection and performance

tracking

• Specific goals or aims

• A proven QI framework

• Protocols

SHM Resource Room. http://www.hospitalmedicine.org. Accessed September 2009.

Page 31: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Risk Assessment Prophylaxis

Low Ambulatory patient without VTE risk factors; observation patient with expected LOS 2 days; same day surgery or minor surgery

Early ambulation

Moderate All other patients (not in low-risk or high-risk category); most medical/surgical patients; respiratory insufficiency, heart failure, acute infectious, or inflammatory disease

UFH 5000 units SC q 8 hours; OR LMWH q day; OR UFH 5000 units SC q 12 hours (if weight < 50 kg or age > 75 years); AND suggest adding IPC

High Lower extremity arthroplasty; hip, pelvic, or severe lower extremity fractures; acute SCI with paresis; multiple major trauma; abdominal or pelvic surgery for cancer

LMWH (UFH if ESRD); OR fondaparinux 2.5 mg SC daily; OR warfarin, INR 2-3; AND IPC (unless not feasible)

Maynard GA, et al. J Hosp Med 2009 Sep 14. [Epub ahead of print]

Page 32: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Maynard GA, et al. J Hosp Med 2009 Sep 14. [Epub ahead of print]

Page 33: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Maynard GA, et al. J Hosp Med 2009 Sep 14. [Epub ahead of print]

Page 34: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Maynard GA, et al. J Hosp Med 2009 Sep 14. [Epub ahead of print]

Page 35: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Attention to Transitions of Care

• Ensure adequate training of the patient– Education on medications, diet, follow up

appointments, lab monitoring, dietary precautions, and adverse reactions or drug-drug interactions

– Education for family– Referral to anticoagulation clinic

• Hospital abstractors must find explicit documentation of this training/education in the chart

Page 36: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Does public reporting accelerate quality improvement?

Page 37: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Changes in National Performance Baseline to Q1, 2009

92.6 91.6 92.8

90.3 89.1 90.3

71.9

91.8

69.7

89.3

0

20

40

60

80

100

Q1,2005*

Q2 2006 Q3 2006 Q4 2006 Q1 2007 Q2 2007 Q3 2007 Q4 2007 Q1 2008 Q2 2008 Q3 2008 Q4 2008 Q1 2009

Pe

rce

nt

Recommended VTE prophylaxis VTE prophylaxis received

//

*National sample of 19,497 Medicare patients undergoing surgery in US hospitals during the first quarter of 2005. (Bratzler, unpublished data

Page 38: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Hospital-acquired ConditionsBackground of the “Never Events”

• Deficit Reduction Act (DRA) of 2005 requires the Secretary of HHS to identify conditions that are:– High cost or high volume (or both); and– Result in the assignment of a case to a DRG

that has a higher payment when present as a secondary diagnosis; and

– Could reasonably have been prevented through the application of evidence-based guidelines.

Page 39: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Hospital-acquired Conditions

10. Deep vein thrombosis/pulmonary embolism following– Total knee replacement– Hip replacement

Page 40: Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH QIOSC Medical Director Dale W. Bratzler, DO, MPH President

Conclusions

• VTE remains a substantial health problem in the US

• VTE prophylaxis remains underutilized

• National performance measures will address both prophylaxis and treatment of VTE across broad hospital populations